WS04.03 Elexacaftor/tezacaftor/ivacaftor (ETI) treatment corrects the salt-losing phenotype in people with cystic fibrosis (pwCF)

Objectives: PwCF have an increased risk for fluid and electrolyte imbalances caused by continuous fluid and salt loss. Congruently, guidelines advocate increased salt intake. Understanding how CFTR modulators affect fluid and electrolyte homeostasis is important to provide guidance for pwCF treated with ETI. In this study, we investigate the effect of ETI treatment on blood pressure and fluid- and electrolyte homeostasis in pwCF.